ArticleLaboratory investigation; a journal of technical methods and pathology2017
Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.
Article in Laboratory investigation; a journal of technical methods and pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Melanoma of unknown primary: a comprehensive review of immune-mediated pathogenesis and therapies.The oncologist · 2025Pooled it
- Early melanoma invasivity correlates with gut fungal and bacterial profiles.The British journal of dermatology · 2022Pooled it
- Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study.Journal for immunotherapy of cancer · 2026Article
- Non-Melanocytic Histopathological Clues for Melanoma Diagnosis: A Practical Review of Solar Elastosis, Stromal Regression, and Epidermal Reaction Patterns. Do Old-School Clues Still Matter?Dermatopathology (Basel, Switzerland) · 2026Review
- Cutaneous Melanoma in Adolescents and Young Adults Versus Older Patients: Clinical and Histopathological Differences in Western Romania.Dermatopathology (Basel, Switzerland) · 2026Article
- Assessment of Risk Factors Correlated with Satellites and In-Transit Metastases in Primary Cutaneous Melanomas.Medicina (Kaunas, Lithuania) · 2026Article
- Functional cytokine-based classification of tumor-infiltrating lymphocytes in melanoma.Scientific reports · 2026Article
- Early Postoperative Recurrence and Systemic Metastases Following Curative Resection of Primary Melanoma of the Lung.Surgical case reports · 2026Article
- DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms.Nature communications · 2025Article
- Malignant melanoma of the conjunctiva metastatic to the parotid gland: a case report.Journal of medical case reports · 2025Article
- Tumoral Melanosis: A Case Series of a Rare Clinical Entity.Dermatology and therapy · 2025Article
- Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy.Clinical and experimental immunology · 2025Review
- Case Report: Shadows of disappearance: the enigma of completely regressed cutaneous melanoma revealed by lymph node metastasis.Frontiers in oncology · 2025Article
- Defining the high-risk category of patients with cutaneous melanoma: a practical tool based on prognostic modeling.Frontiers in molecular biosciences · 2025Article
- Contribution of Keratinocytes in Skin Cancer Initiation and Progression.International journal of molecular sciences · 2024Review
- Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Strategies for improving the performance of prediction models for response to immune checkpoint blockade therapy in cancer.BMC research notes · 2024Article
- Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma.Expert review of molecular diagnostics · 2024Review
- Deciphering the immune reaction leading to spontaneous melanoma regression: initial role of MHCIICancer immunology, immunotherapy : CII · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Though not required currently for staging, regression is a histopathologic parameter typically reported upon diagnosis of an invasive primary cutaneous melanoma. The studies examining the prognostic significance of regression in patient outcome have yielded controversial findings; likely because the definition and assessment of regression have not been consistent, in addition to subjectivity of pathologists' interpretation. Regression is histologically characterized by variable decrease in the number of melanoma cells accompanied by the presence of a host response consisting of dermal fibrosis, inflammatory infiltrate, melanophages, ectatic blood vessels, epidermal attenuation, and/or apoptosis of keratinocytes or melanocytes; the relative extent of these features depends on the stage of the regression. However, the magnitudes to which these individual changes must be present to meet the threshold of histologic regression have not been well defined or agreed upon, and thus, the definition and classification of histologic regression in melanoma varies considerably among institutions and even among individual pathologists. In order to determine the clinical significance of histologic analysis of regression, there is a compelling need for a universal scheme to objectively define and assess histologic regression in primary cutaneous melanoma, so that the biologic and prognostic significance of this process may be completely understood.Laboratory Investigation advance online publication, 27 February 2017; doi:10.1038/labinvest.2017.8.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.